When Will Invega Sustenna's Patents Expire?
The primary patent protecting Invega Sustenna (paliperidone palmitate extended-release injectable suspension) is set to expire in October 2025 [1]. This expiration date is crucial for understanding potential market changes and the introduction of generic alternatives.
What Happens After Invega Sustenna's Main Patent Expires?
Following the expiration of key patents, generic versions of Invega Sustenna may become available. This typically leads to increased competition and potentially lower prices for the medication [2].
Are There Other Patents on Invega Sustenna?
In addition to the main patent expiring in 2025, there may be other patents related to Invega Sustenna's formulation, manufacturing process, or specific uses [1][3]. These secondary patents could potentially extend market exclusivity for certain aspects of the drug. DrugPatentWatch.com tracks these patent landscapes [1].
Can Generic Versions of Invega Sustenna Be Launched Before Patent Expiry?
Generally, generic manufacturers must wait for patents to expire before launching their products. However, in some cases, legal challenges or agreements between brand-name and generic companies can influence launch timelines [2].
What is the Significance of the October 2025 Expiry Date?
The October 2025 patent expiry date is a significant marker as it is expected to open the door for the introduction of interchangeable generic paliperidone palmitate extended-release injectable suspension products. This could lead to increased access and cost savings for patients and healthcare systems [2].
How Does Invega Sustenna Work?
Invega Sustenna is an atypical antipsychotic used to treat schizophrenia and schizoaffective disorder [4]. It is a long-acting injectable formulation of paliperidone, an active metabolite of risperidone. The extended-release formulation allows for less frequent dosing, typically once a month, which can improve adherence for patients [4][5].
Who Manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [4].
What Are the Potential Risks or Side Effects of Invega Sustenna?
Common side effects of Invega Sustenna can include injection site reactions, headache, and insomnia. More serious side effects, though less common, can occur and include movement disorders like tardive dyskinesia and metabolic changes [4][5].
How Does Invega Sustenna Compare to Other Antipsychotics?
Invega Sustenna is one of several long-acting injectable antipsychotics available. It offers a monthly dosing schedule, which is an advantage for patient adherence compared to daily oral medications [5]. Its efficacy and side effect profile are similar to other atypical antipsychotics, with the specific choice of medication often depending on individual patient needs and tolerance [4][5].
Where Can I Find More Information on Invega Sustenna Patents?
Detailed information on patents related to Invega Sustenna, including expiry dates and any ongoing litigation, can be found on resources like DrugPatentWatch.com [1].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Invega Sustenna Patents. Retrieved from https://drugpatentwatch.com/
[2] (Information synthesized from general knowledge of pharmaceutical patent expirations and generic drug market entry).
[3] (Information synthesized from general knowledge of patent landscapes for pharmaceutical products).
[4] Janssen Pharmaceuticals. (n.d.). Invega Sustenna Prescribing Information.
[5] (Information synthesized from general knowledge of long-acting injectable antipsychotics).